Condition
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Total Trials
4
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Recruiting3
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06867991Phase 3RecruitingPrimary
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
NCT06510283Phase 2RecruitingPrimary
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
NCT05280600RecruitingPrimary
Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
NCT02443350UnknownPrimary
Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing Area
Showing all 4 trials